Open an account

Zyversa Therapeutics

ZVSA · NASDAQ

$0.001+$0.0008 (+400.00%)TodayMarket closed ·
Prev close $0.0002

About ZVSA

ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Weston, Florida and currently employs 6 full-time employees. The company went IPO on 2021-12-21. The firm is focused on leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases. Its lead renal drug candidate, Cholesterol Efflux Mediator VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is in development to treat multiple renal indications. Its lead anti-inflammatory drug candidate, Inflammasome ASC Inhibitor IC 100, is a humanized monoclonal antibody in development to treat multiple inflammatory diseases. Its renal pipeline is initially focused on rare, chronic glomerular diseases. Its lead indication for VAR 200 is focal segmental glomerulosclerosis. VAR 200’s active ingredient, 2-hydroxypropyl-beta-cyclodextrin, comprises seven sugar molecules bound together in a 3-D ring with a hydrophobic core and hydrophilic exterior. VAR 200 mediates cholesterol efflux both passively and actively by interacting with hydrophilic components of the glomerular membrane.

Employees
6
Headquarters
Weston, Florida
Listed
Dec 21, 2021
Sector
Health Care
Industry
Biotechnology
Website
zyversa.com

ZVSA key statistics

Market cap
850.00K
Price-earnings ratio
0.00
Dividend yield
—
Average volume
21.00K
Volume
889
Open price
$0.0005
High today
$0.001
Low today
$0.0005
52 Week high
$0.30
52 Week low
$0.0002

Zyversa Therapeutics (ZVSA) at a glance

As of Oct 20, 2026, Zyversa Therapeutics (ZVSA) shares are priced at $0.001, giving the company a market cap of 850.00K and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.0005 and $0.001. The current price is 100.0% above the day's low and 0.0% below its high.

Volume so far is 889 shares, below the average of 21.00K shares a day.

Over the past year Zyversa Therapeutics has ranged from $0.0002 to $0.30, and now sits 0% of the way up that range.

Zyversa Therapeutics met or beat analyst EPS estimates in 3 of the last 6 quarters. In Q1 FY26 it reported -$0.22 per share against an estimate of $0.00.

ZVSA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 6 quarters, by 31.3% on average.

  1. Q3 FY23: reported -$31.50 per share against an estimate of -$57.12
  2. Q4 FY23: reported -$136.80 per share against an estimate of -$21.83
  3. Q1 FY24: reported -$4.53 per share against an estimate of -$3.77
  4. Q2 FY24: reported -$3.31 per share against an estimate of -$3.83
  5. Q3 FY24: reported -$2.43 per share against an estimate of -$3.77
  6. Q1 FY26: reported -$0.22 per share against an estimate of $0.00

ZVSA news

  • ZyVersa Therapeutics Releases Mid-Year Shareholder Letter Highlighting Recent Corporate Developments And R&D Progress Including Closing Two Financial Transactions Providing Access To $12M In Capital

  • Press releaseGlobe Newswire

    ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress

  • Vandana Singh

    Why Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday?

  • Press releaseGlobe Newswire

    ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol Efflux Mediator™ VAR 200

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Avi Kapoor

    Dow Jumps 400 Points; Yum! Brands Posts Downbeat Earnings

Similar companies

Companies in the same industry as Zyversa Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.